NCT00093951
Completed
Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase II Study of the Efficacy and Safety of SGS742 in Subjects With Mild to Moderate Alzheimer's Disease
Saegis Pharmaceuticals42 sites in 1 country280 target enrollmentApril 2004
ConditionsAlzheimer's Disease
DrugsSGS742
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Alzheimer's Disease
- Sponsor
- Saegis Pharmaceuticals
- Enrollment
- 280
- Locations
- 42
- Status
- Completed
- Last Updated
- 16 years ago
Overview
Brief Summary
The purpose of this trial is to determine the effect of a new drug, SGS742, on memory and cognition in patients with mild to moderate Alzheimer's disease.
Detailed Description
SGS742 is a GABA(B) receptor antagonist. It is an orally active drug and possesses neurochemical and psychopharmacologic features that suggest it could improve memory and cognition in humans. The primary objective of the SGS742 clinical trial will be to determine the effect of SGS742 on memory and cognition in individuals diagnosed with mild to moderate Alzheimer's disease. The duration of the study is 3 months with 5 clinic visits.
Investigators
Eligibility Criteria
Inclusion Criteria
- •55 to 90 years of age
- •Diagnosed with mild to moderate Alzheimer's disease
- •Willing caregiver
- •In general good health
Exclusion Criteria
- •Call 1-877-MY-MEMORY and ask to be referred to a study center located near you for entry criteria information.
- •Prohibited Meds:
- •Alzheimer's medications (Aricept, Exelon, Remydl, Nemenda)
Outcomes
Primary Outcomes
Not specified
Study Sites (42)
Loading locations...
Similar Trials
Completed
Phase 2
Study of MK0677 for the Treatment of Alzheimer's Disease (0677-030)(COMPLETED)Alzheimer's DiseaseNCT00074529Merck Sharp & Dohme LLC512
Completed
Phase 2
A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's DiseaseParkinson's Disease With Cognitive ImpairmentsNCT01211587Newron Pharmaceuticals SPA103
Completed
Phase 2
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.Alzheimers DiseaseDementiaAlzheimers Disease, FamilialNCT04623242Washington University School of Medicine194
Completed
Phase 2
Investigation of Memantine in the Treatment of Memory, Concentration or Attention ProblemsMemory DisorderRetention Disorder, CognitiveSubjective Cognitive ImpairmentMemory, Concentration or Attention ProblemsNCT01261741Merz Pharmaceuticals GmbH299
Completed
Phase 2
Efficacy, Safety and Tolerability of Tideglusib to Treat Mild-to-Moderate Alzheimer's Disease PatientsAlzheimer's DiseaseNCT01350362Noscira SA306